Trial
NCT05756166
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Intervention
Biopsy
Why stopped
Funding ended
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-24